Producer
Siegfried AG
Swiss contract development and manufacturing organization (CDMO; SIX: SFZN; HQ Zofingen, Aargau, Switzerland; ~CHF 1.6B revenue); a major global CDMO for controlled substance APIs including buprenorphine, methadone, fentanyl, and psychedelic-based investigational compounds. Siegfried holds Schedule I/II controlled substance manufacturing licenses in Switzerland (Swissmedic), Germany (BfArM), and the US (DEA), enabling it to manufacture opioid APIs across multiple jurisdictions. Buprenorphine API production occurs at Siegfried's Zofingen Switzerland and Hameln Germany sites. Siegfried is increasingly relevant to buprenorphine supply as generic manufacturers expanding post-Suboxone patent cliff seek additional qualified suppliers beyond Noramco and Macfarlan Smith. Siegfried's business also covers non-opioid APIs, intermediates, and finished dosage form contract manufacturing — representing a rare full-service CDMO with DEA Schedule I capability. Swiss CDMO neutrality and multi-jurisdictional licensing makes Siegfried a de-risking option for pharmaceutical companies seeking non-US/non-UK buprenorphine API supply.
2
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
2 inputs Siegfried AG supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Siegfried AG makes — pick one to see the full supply chain.
Where they make it
2 facilities
Siegfried AG Evionnaz Switzerland Controlled Substance Manufacturing →
CHValais · lab
Siegfried AG's Evionnaz, Valais Switzerland facility is a primary site for pharmaceutical controlled substance API manufacturing, operating under Swiss regulatory authority (Swissmedic) and international INCB quota framework. Produces pharmaceutical-grade fentanyl and other opioid APIs for medical use.
Siegfried AG — Zofingen Controlled Substance API Plant →
CHAargau · manufacturing
Siegfried AG primary API manufacturing campus in Zofingen, Switzerland. Swissmedic-licensed controlled substance API production including buprenorphine, methadone, and other Schedule I/IV substances under Swiss Narcotics Act and INCB quota framework. Swiss manufacturing neutrality and multi-jurisdictional controlled substance licensing make this a key third-party buprenorphine API source for generic manufacturers. Source: https://www.siegfried.ch/en/locations/zofingen/
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Traditional Opioid APIs (CDMO)
50%Psychedelic Investigational APIs
20%Non-Controlled Pharma CDMO
30%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Siegfried is tracked as a controlled substance CDMO for traditional opioids (buprenorphine, methadone, fentanyl — the addiction treatment and pain management supply chain). But Siegfried has also become a critical manufacturing partner for the psychedelic medicine clinical trial wave: producing GMP-grade psilocybin for cancer anxiety clinical trials, MDMA for PTSD trials, and ketamine formulations. The addiction treatment supply chain and the emerging psychedelic psychiatry supply chain both run through the same Swiss CDMO, with the same DEA Schedule I/II manufacturing licenses, the same Swiss chemistry expertise, and the same Zofingen facility. The chronic pain/addiction management pharmaceutical world and the revolutionary psychedelic mental health treatment world share a common upstream manufacturer — and share the same regulatory risk if Swiss or US drug scheduling changes affect Siegfried's licenses.
Siegfried AG ↗Concentration2023
Siegfried AG (Zofingen, Switzerland) is one of the few companies globally authorized to manufacture pharmaceutical fentanyl API under Swiss Swissmedic regulation and INCB quota framework. Siegfried's controlled substance API manufacturing business is a relatively low-profile segment of a CHF 1.5B pharmaceutical contract manufacturer — most industry observers know Siegfried as a contract CDMO rather than as a critical supplier in the anesthesia supply chain. Siegfried's Evionnaz Valais facility is a major European node for pharmaceutical controlled substance production.
Contract Pharma (independent trade press) ↗Origin2023
Siegfried AG was founded in 1873 in Zofingen, Aargau, Switzerland — a canton known for precision manufacturing and pharmaceutical chemistry. Switzerland's political neutrality, regulatory reliability, and pharmaceutical expertise made it the ideal home for a controlled substance CDMO: Swiss facilities can produce Schedule I/II controlled substances for export to both the US (DEA-licensed) and European (national drug authority-licensed) markets under international narcotics treaty frameworks. Siegfried built deep expertise in opioid alkaloid chemistry over 150 years, eventually becoming the go-to CDMO for pharmaceutical companies needing GMP-controlled substance API manufacturing.
Siegfried AG ↗